A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24-mg Starting Dose, But Have a Better Safety Profile
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Lenvatinib (Primary)
- Indications Thyroid cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eisai Inc
- 16 May 2017 Planned number of patients changed from 300 to 161.
- 16 May 2017 Planned End Date changed from 31 Jan 2020 to 30 Oct 2020.
- 16 May 2017 Planned primary completion date changed from 31 May 2019 to 30 Oct 2020.